As of Nov 27
| +0.39 / +0.82%|
The 17 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 46.13, with a high estimate of 58.35 and a low estimate of 38.45. The median estimate represents a -3.31% decrease from the last price of 47.71.
The current consensus among 17 polled investment analysts is to Buy stock in Novozymes A/S. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.